Drug Prices
Commentary
Congress Eyes Regulating Drug Ads, It Won’t Mean Lower Prices
“Knowing what something costs before buying it is just common sense.” That’s how Sen. Chuck Grassley, R-Iowa, justified a bill he introduced in January to require drug companies to include a medicine’s list price in their advertisements. Unfortunately, his Drug-price Transparency for Consumers, or DTC, Act — co-sponsored by Sen. ...
Commentary
The World’s Medicine Chest
Just released from PRI – read The World’s Medicine Chest, the latest book from PRI President, CEO and Thomas W. Smith Fellow in Health Care Policy. The World’s Medicine Chest explores how America became the world’s leader in biopharmaceutical innovation through market capitalism. Click here to register to watch a special live ...
Book
Read the new book from Sally Pipes “The World’s Medicine Chest”
Just released from PRI – read The World’s Medicine Chest, the latest book from PRI President, CEO and Thomas W. Smith Fellow in Health Care Policy. <The World’s Medicine Chest explores how America became the world’s leader in biopharmaceutical innovation through market capitalism. Click here to register to watch a special ...
Commentary
Insulin prices are falling due to market forces — no price caps required
California State Sen. Scott Wiener, D-San Francisco, recently introduced legislation that would cap cost-sharing for insulin at $35 a month, regardless of whether a patient has public or private insurance. It’s a popular idea. But it may not be necessary. The cost of insulin has been falling due to market ...
Commentary
Patients Pay Dearly for Biden’s Pricing Mess
On Jan. 17, just days before leaving office, the Biden administration announced the next 15 prescription drugs dispensed through Medicare Part D that will be subject to price controls on Jan. 1, 2027, under the terms of the Inflation Reduction Act. Among them is the blockbuster semaglutide, a prescription medication ...
Commentary
RFK Jr.’s Confirmation Hearings Can’t Leave This Question Unanswered
On this Wednesday and Thursday, two powerful Senate committees will hold confirmation hearings for Robert F. Kennedy Jr., President Trump’s nominee to lead the Department of Health and Human Services. RFK Jr. is no stranger to controversy. But his most radical policy position may be one that relatively few people ...
Commentary
Creative Counting Can’t Fix The Inflation Reduction Act’s Flaws
Just three days before President Biden left office, his appointees tried to tie incoming Trump staffers’ hands on a health policy decision that affects millions of Americans and tens of billions in federal spending. On January 17, the Centers for Medicare & Medicaid Services announced a new list of 15 ...
Blog
Read about a last minute Biden administration plan the Trump administration should undo
CMS’ Drug Price Controls Have Expanded to the Next 15 Medicare Part D Drugs
For every complex problem there is an answer that is clear, simple, and wrong. H.L. Mencken Back in 2022, the Biden Administration reasoned that drug costs are too high and devised a clear and simple answer: incorporate a Maximum Fair Price (MFP) provision into the Inflation Reduction Act of 2022 ...
Drug Innovation
PRI Responds to CMS Adding 15 Additional Drugs That Will Be Subjected to Government Price Controls
PRI’s scholars responded to today’s action by the Centers for Medicare & Medicaid (CMS) announcing 15 additional drugs under Medicare Part D that will be subject to government price setting effective January 1, 2027. The action was authorized by the Inflation Reduction Act signed by President Biden in August 2022. ...
Biosimilars
The Biosimilar Promise
Reforms Can Improve Competition and Generate More Savings
Reforms Can Improve Competition and Generate More Savings By Wayne Winegarden | January 7, 2025 READ PDF Executive Summary Reforms that will strengthen the biosimilar market and expand savings opportunities include: Reforming (ideally repealing) the Inflation Reduction Act’s price control measures. Improving the incentives underlying the current buy-and-bill system to ...
Congress Eyes Regulating Drug Ads, It Won’t Mean Lower Prices
“Knowing what something costs before buying it is just common sense.” That’s how Sen. Chuck Grassley, R-Iowa, justified a bill he introduced in January to require drug companies to include a medicine’s list price in their advertisements. Unfortunately, his Drug-price Transparency for Consumers, or DTC, Act — co-sponsored by Sen. ...
The World’s Medicine Chest
Just released from PRI – read The World’s Medicine Chest, the latest book from PRI President, CEO and Thomas W. Smith Fellow in Health Care Policy. The World’s Medicine Chest explores how America became the world’s leader in biopharmaceutical innovation through market capitalism. Click here to register to watch a special live ...
Read the new book from Sally Pipes “The World’s Medicine Chest”
Just released from PRI – read The World’s Medicine Chest, the latest book from PRI President, CEO and Thomas W. Smith Fellow in Health Care Policy. <The World’s Medicine Chest explores how America became the world’s leader in biopharmaceutical innovation through market capitalism. Click here to register to watch a special ...
Insulin prices are falling due to market forces — no price caps required
California State Sen. Scott Wiener, D-San Francisco, recently introduced legislation that would cap cost-sharing for insulin at $35 a month, regardless of whether a patient has public or private insurance. It’s a popular idea. But it may not be necessary. The cost of insulin has been falling due to market ...
Patients Pay Dearly for Biden’s Pricing Mess
On Jan. 17, just days before leaving office, the Biden administration announced the next 15 prescription drugs dispensed through Medicare Part D that will be subject to price controls on Jan. 1, 2027, under the terms of the Inflation Reduction Act. Among them is the blockbuster semaglutide, a prescription medication ...
RFK Jr.’s Confirmation Hearings Can’t Leave This Question Unanswered
On this Wednesday and Thursday, two powerful Senate committees will hold confirmation hearings for Robert F. Kennedy Jr., President Trump’s nominee to lead the Department of Health and Human Services. RFK Jr. is no stranger to controversy. But his most radical policy position may be one that relatively few people ...
Creative Counting Can’t Fix The Inflation Reduction Act’s Flaws
Just three days before President Biden left office, his appointees tried to tie incoming Trump staffers’ hands on a health policy decision that affects millions of Americans and tens of billions in federal spending. On January 17, the Centers for Medicare & Medicaid Services announced a new list of 15 ...
Read about a last minute Biden administration plan the Trump administration should undo
CMS’ Drug Price Controls Have Expanded to the Next 15 Medicare Part D Drugs
For every complex problem there is an answer that is clear, simple, and wrong. H.L. Mencken Back in 2022, the Biden Administration reasoned that drug costs are too high and devised a clear and simple answer: incorporate a Maximum Fair Price (MFP) provision into the Inflation Reduction Act of 2022 ...
PRI Responds to CMS Adding 15 Additional Drugs That Will Be Subjected to Government Price Controls
PRI’s scholars responded to today’s action by the Centers for Medicare & Medicaid (CMS) announcing 15 additional drugs under Medicare Part D that will be subject to government price setting effective January 1, 2027. The action was authorized by the Inflation Reduction Act signed by President Biden in August 2022. ...
The Biosimilar Promise
Reforms Can Improve Competition and Generate More Savings
Reforms Can Improve Competition and Generate More Savings By Wayne Winegarden | January 7, 2025 READ PDF Executive Summary Reforms that will strengthen the biosimilar market and expand savings opportunities include: Reforming (ideally repealing) the Inflation Reduction Act’s price control measures. Improving the incentives underlying the current buy-and-bill system to ...
